No Data
NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company's Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of car
Express News | NRX Pharmaceuticals Inc: Expect to Complete Stability Portion of Our New Drug Application for Ketamine by September
Express News | NRX Pharmaceuticals: Reached 9-Month Stability Point With Its Ketamine Formulation (NRX-100), Initiated 3 Manufacturing Lots for Future Drug Release
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the ...
NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital
NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital
Express News | Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $43